title: [Wilson's disease--critical deterioration under high-dose parenteral penicillamine therapy].
abstract: A 31-year-old man with Wilson's disease, not treated for the past 4 1/2 years, was admitted to hospital with brain concussion after a fall. While receiving penicillamine, 1 g i.v. four times daily, the neurological signs worsened and akinesia, mutism, tachy- and bradyarrhythmias, as well as transitory respiratory insufficiency developed. Serum copper concentration on the sixth day of treatment was markedly decreased to 28 micrograms/dl, rising to 60 micrograms/dl on the ninth day. 24-hour urinary copper excretion was at first 4500-5000 micrograms. Only after drastic reduction of the penicillamine dosage to 600 mg three times daily was there any improvement and after 11 weeks the patient was again able to walk and was discharged. Marked, mainly hepatic, copper depletion from the high penicillamine dosage was the likely cause of the patient's initial deterioration. To avoid cerebral complications penicillamine should be administered in gradually increasing doses.
authors.affiliation: Neurologische Klinik mit Poliklinik, Universität Erlangen-Nürnberg.
authors.forename: M J
authors.initials: MJ
authors.lastname: Hilz
authors.forename: K F
authors.initials: KF
authors.lastname: Druschky
authors.forename: J
authors.initials: J
authors.lastname: Bauer
authors.forename: B
authors.initials: B
authors.lastname: Neundörfer
authors.forename: G
authors.initials: G
authors.lastname: Schuierer
mesh_terms: D000328:Adult; D002908:Chronic Disease; D003300:Copper / Q000032:analysis; D006527:Hepatolenticular Degeneration / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D009460:Neurologic Examination; D010349:Patient Compliance; D010396:Penicillamine / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D003300:Copper; D010396:Penicillamine
vernacular_title: Morbus Wilson--kritische Verschlechterung unter hochdosierter parenteraler Penicillamin-Therapie.